Beyond Trastuzumab
 

This new article (full-text via link) seems to provide the answers (the authors had read our minds. :)

"Beyond Trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer."

http://www.ncbi.nlm.nih.gov/pmc/arti...2/?tool=pubmed


*******************
Today, 04:50 AM
I appreciate how helpful you are with research/info, Jackie. Thank you.

This is from the link you shared:

Summary of Key Conclusions

• HER2, estrogen receptor (ER)–positive patients with early-stage breast cancer at significantly increased risk of recurrent disease within 2.5 years after diagnosis
  • Peak in annual recurrence rate at 2 years in HER2-positive group
• AIs reduce the risk of recurrence in HER2-positive patients
  • Trastuzumab should be considered for ER-positive, HER2-positive patients given that inhibition of growth factor signaling may increase response to endocrine therapy

----------------
So what I get out of this is that Her2 pos, ER pos patients are given the hormone blockers because of their increased risk of reoccurence within the first 2 1/2 years after diagnosis. We know the benifits of Trastuzumab in this picture too.

I would assume that the majority of patients are utilizing every big gun we have to fight this and I am wondering what the research shows as to results as I don't have a clear picture of that.

Does anybody know the actual percentage of Her2 positive breast cancer patients that experience metastisis despite full treatment? I would appreciate knowing. Anybody here's oncologist discuss rate of metastisis and survival statistics for those fully treated with all the standards of care: surgery, chemo, radiation, herceptin, hormone blockers?

Thank you very much,

Paula

03-03-2012, 07:05 PM
Hopeful and Barbara2 have posted a couple of recent articles on this thread where Rich also provided some links:

http://her2support.org/vbulletin/sho...ce+rate&page=2


03-03-2012, 08:00 AM
Does anybody have current statistics on the reoccurence rate and percentage of those who end up with metastisis for those who are Her2 positive who have surgery, chemo, Herceptin, radiation, and hormone blockers? I would be interested in published research results as well as what people here are hearing from their own oncologists.

Thanks,

Paula